- Termination of Registration of a Class of Security under Section 12(g) (15-12G)
19 Marzo 2009 - 6:12PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File Number: 001-16043
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
221
West Grand Avenue
Montvale,
New Jersey 07645
(Address
of Principal Executive Offices)
(201)
934-5000
(Address,
including zip code, and telephone number, including area code, of registrant's
principal executive offices)
Common
Stock, $0.01 Par Value
(Title of
each class of securities covered by this Form)
None
(Titles
of all other classes of securities for which a duty to file reports under
section 13(a) or 15(d) remains)
Please place an X in the box(es) to
designate the appropriate rule provision(s) relied upon to terminate or suspend
the duty to file reports:
Rule
12g-4(a)(1)
|
x
|
Rule
12g-4(a)(2)
|
o
|
Rule
12h-3(b)(1)(i)
|
x
|
Rule
12h-3(b)(1)(ii)
|
o
|
Rule
15d-6
|
o
|
Approximate number of holders of record
as of the certification or notice date: 296
Pursuant to the requirements of the
Securities Exchange Act of 1934, Synvista Therapeutics, Inc. has caused this
certification and notice to be signed on its behalf by the undersigned duly
authorized person.
|
|
|
|
Date: March
19, 2009
|
By:
|
/s/
Noah Berkowitz, M.D., Ph.D.
|
|
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
|
Grafico Azioni Synvista Therapeutics (CE) (USOTC:SYNI)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Synvista Therapeutics (CE) (USOTC:SYNI)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Synvista Therapeutics Inc (CE) (OTCMarkets): 0 articoli recenti
Più Synvista Therapeutics (OTC) Articoli Notizie